Вся информация, размещенная в данном разделе веб-сайта, предназначена исключительно
для специалистов здравоохранения – медицинских и фармацевтических работников. Если Вы не являетесь специалистом здравоохранения, в соответствии с положениями действующего законодательства РФ Вы не имеете права доступа к информации, размещенной в данном разделе веб-сайта, в связи с чем просим Вас незамедлительно покинуть данный раздел веб-сайта.
Подтвердите что вы являетесь специалистом,
ответив на вопрос:
Как называются бактерии, отдельные штаммы которых обладают патогенными свойствами и могут вызывать инфекции моче-полового тракта, особенно если перед этим пациенты принимали большое количество антибиотиков, препаратов, подавляющих иммунитет
или подвергались различным инвазивным методам обследования?
1. Reid G. Regulatory and clinical aspects of dairy probiotics. FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Powder Milk with Live Lactic Acid Bacteria. Cordoba, Argentina, 2001: 1-34.
2. Hoesl C.E., Altwein J.E. The probiotic approach: an alternative treatment option in urology. Eur Urol, 2005; 47: 288–96.
3. Gibson G.R., Roberfroid M.B. Dietary modulation of the human colonic micro-biota: introducing the concept of prebiotics. J Nutr 1995: 125: 1401-12.
4. Tanaka R., Takayama H., Morotomi М. e a. Effect of administration TOS and Bifidobacterium breve 4006 on the human fecal flora. Bifidobacteria microflora 1983; 2: 17-24.
5. Roberfroid M.B. Prebiotics and probiotics: are they functional foods? Am J Clin Nutr 2000: 71 (Suppl 6): 1682S-87S.
6. Van Loo J., Cummings J., Delzenne N., e. a. Functional food properties of non-digestible oligosaccharides: a consensus report from the HVDO project (DGXII AIRII-CT94-1095). Br J Nutr. 1999; 81(2): 121-32.
7. Rowland I.R., Tanaka R. The effects of transgalactosylated oligosaccharides on gut flora metabolism in rats associated with a human faecal microflora. J AppI Bacteriol 1993: 74: 667-74.
8. Eaton T.J., Gasson M.J. Molecular screening of Enterococcus virulence determinants and potential for genetic exchange between food and medical isolates. Appl Environ Microbiol. 2001; 67(4): 1628-35.
9. Holzapfel W.H., Haberer P., Geisen R., et al. Taxonomy and important features of probiotic microorganisms in food and nutrition. Am J Clin Nutr 2001;73(2 Suppl):365S-73S.
10. Walker R., Buckley M. Probiotic microbes: the scientific basis. A report from the American Academy of Microbiology, 2006.
11. Marcos A., Wärnberg J., Nova E., et al.The effect of milk fermented by yogurt cultures plus Lactobacillus casei DN-114001 on the immune response of subjects under academic examination stress. Eur J Nutr. 2004; 43(6): 381-9.
12. Monachese M., Burton J.P., Reid G. Bioremediation and tolerance of humans to heavy metals through microbial processes: a potential role for probiotics? Appl Environ Microbiol. 2012; 78(18): 6397-404.
13. Guidelines for the Evaluation of Probiotics in Food. Joint FAO/WHO (Food and Agriculture Organization/World Health Organisation) Working Group. London, Ontario, Canada: 2002.
14. Saavedra J. M. Clinical applications ofprobiotic agents. Am J Clin Nutr. 2001; 73(6): 1147S-51S.
15. Madsen K. I. The use ofprobiotics in gastrointestinal disease. Can J Gastroenterol. 2001; 15 (S12): 817-22.
16. Kailasapathy K., Chin J. Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp. Immunol Cell Biol. 2000; 78(1): 80-8.
18. Adams M. R., Marteau P. On the safety of lactic acid bacteria from food. Int J Food Microbiol. 1995; 27: 263-4.
19. Naidu A. S., Bidlack W. RClemens., R. A. Probiotic spectra of lactic acid bacteria (LAB). Crit Rev Food Sci Nutr 1999; 39:13-126.
20. Reid, G. Safety of Lactobacillus strains as probiotic agents. Clin. Infect. Dis 2002; 35: 349-50.
21. Doron S., Snydman D.R. Risk and safety of probiotics. Clin Infect Dis. 2015; 60 Suppl 2: S129-34.
22. Salminen S, von Wright A, Morelli L, Marteau P, Brassart D, de Vos WM, et al. Demonstration of safety of probiotics - a review. Int J Food Microbiol 1998; 44: 93-106.
23. Borriello S.P., Hammes W.P., Holzapfel W., e a. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 2003; 36: 775–80.
24. Marteau P, Seksik P, Jian R.:Probiotics and health: new facts and ideas. Curr Opin Biotechnol. 2002; 13(5): 486-9.
25. Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JMT. Lactobacillusendocarditis caused by a probiotic organism. Clin Microbiol Infect 1999;5:290-2.
26. Rautio M., Jousimies-Somer H., Kauma H., e. a. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999; 28: 1159-60.
27. Salminen M.K., Rautelin H., Tynkkynen S., e.a. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis. 2004; 38(1):62-9.
28. Land M.H., Rouster-Stevens K., Woods C.R., e.a. Lactobacillus sepsis associated with probiotic therapy. Pediatrics. 2005; 115(1): 178-81.
29. De Groote M.A., Frank D.N., Dowell E., e.a. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J. 2005; 24(3): 278-80.
30. Sadowska-Krawczenko I., Paprzycka M., Korbal P., et al. Lactobacillus rhamnosus GG suspected infection in a newborn with intrauterine growth restriction. Benef Microbes. 2014; 5(4): 397-402.
31. Vahabnezhad E., Mochon A.B., Wozniak L.J., Ziring D.A. Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol. 2013; 47(5): 437-9.
32. Kubiszewska I., Januszewska M., Rybka J., Gackowska L. Lactic acid bacteria and health: are probiotics safe for human? Postepy Hig Med Dosw (Online). 2014; 68: 1325-34.
33. Hennequin C., Kauffmann-Lacroix C., Jobert A., e.a. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis. 2000; 19(1): 16-20.
34. Cherifi S., Cherifi S., Robberecht J., Miendje Y. Saccharomyces cerevisiae fungemia in an elderly patient with Clostridium difficile colitis. Acta Clin Belg. 2004; 59(4): 223-4.
36. Lestin F., Pertschy A., Rimek D. Fungemia after oral treatment with Saccharomyces boulardii in a patient with multiple comorbidities. Dtsch Med Wochenschr. 2003 Nov 28;128(48):2531-3.
37. Thygesen J.B., Glerup H., Tarp B. Saccharomyces boulardii fungemia caused by treatment with a probioticum. BMJ Case Rep. 2012; pii: bcr0620114412.
38. Eren Z., Gurol Y., Sonmezoglu M., et al. Saccharomyces cerevisiae fungemia in an elderly patient following probiotic treatment. Mikrobiyol Bul. 2014; 48(2): 351-5.
39. Santino I., Alari A., Bono S., et al. Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum. Int J Immunopathol Pharmacol. 2014; 27(1): 143-6.
40. Munoz Р., Bouza E., Cuenca-Estrella M., e. a. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005; 40(11):1625-34.
41. Oggioni M.R., Pozzi G., Balensin P.E., e.a. Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis. J Clin Microbiol 1998; 36: 325–6.
42. Richard V., Auwera P., Snoeck R., e.a. Nosocomial bacteremia caused by Bacillus species. Eur J Clin Microbiol Infect Dis 1988; 7: 783–5.
43. Gardiner D., Murphey S., Ossman E., Jungkind D. Prevalence and acquisition of vancomycin-resistant enterococci in a medical intensive care unit. Infect Control Hosp Epidemiol, 2002; 23: 466-8.
44. Szajewska H, et al. Use of Probiotics for Management of Acute Gastroenteritis: A Position Paper by the ESPGHAN Working Group for Probiotics and Prebiotics. JPGN 2014; 58 (4): 531-9.
45. Salminen M.K., Tynkkynen S., Rautelin H., e.a. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis. 2002; 35(10): 1155-60.
47. Allen S.J., Martinez E.G., Gregorio G.V., Dans L.F. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010 Nov 10;11:CD003048.
48. Szajewska H., Skórka A., Ruszczyński M., Gieruszczak-Białek D. Meta-analysis: Lactobacillus GG for treating acute gastroenteritis in children--updated analysis of randomised controlled trials. Aliment Pharmacol Ther. 2013; 38(5): 467-76.
49. de la Cabada Bauche J, Dupont HL. New Developments in Traveler's Diarrhea. Gastroenterol Hepatol (N Y). 2011; 7(2): 88-95.
50. Connor B.A., Landzberg B.R. Prevention and treatment of acute traveler's diarrhea. Infect Med 2004; 21(1): 18-9.
51. McFarland L.V. Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis. 2007; 5(2): 97-105.
52. Cremonini F., Di Caro S., Nista E.C., e.a. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2002; 16(8): 1461-7.
54. Hempel S., Newberry S.J., Maher A.R., et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med. 2012; 157(12): 878-88.
55. Castagliuolo I., Riegler M.F., Valenick L., еt аl. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999; 67(1): 302-7.
56. Boyanova L., Mentis A., Gubina M., e.a. The status of antimicrobial resistance of Helicobacter pylori in Еastern Europe. Clin Microbiol Infect 2002; 8 (7): 388-96
57. Tong J.L., Ran Z.H., Shen J., e.a. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007; 25(2): 155-68.
58. Zou J, Dong J, Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter. 2009; 14(5): 97-107.
59. Chenoll E., Casinon B., Bataller E. et al. Novel probiotic Bifidobacterium bifidum CECT 7366 strain active against the pathogenic bacterium Helicobacter pylori. Applied and environmental microbiology, 2011: 1335-1343.
60. Dimidi E., Christodoulides S., Fragkos K.C., et al. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2014; 100(4): 1075-84.
61. Saavedra J.M., Abi-Hanna A., Moore N., et al. Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety. Am J Clin Nutr. 2004; 79(2): 261-7.
62. Kianifar H., Ahanchian H., Grover Z., et al. Synbiotic in the management of infantile colic: A randomised controlled trial. J Paediatr Child Health. 2014; 50(10): 801-5.
63. Indrio F., Di Mauro A., Riezzo G., et al. Prophylactic Use of a Probiotic in the Prevention of Colic, Regurgitation, and Functional Constipation: A Randomized Clinical Trial. JAMA Pediatr. 2014; 168(3): 228-33.
64. Wong V.W., Won G.L., Chim A.M., et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol. 2013; 12(2): 256-62.
65. Reid G., Bruce A. W., Fraser N., e.a. Oral probiotics can resolve urogenital infections. FEMS Immunol. Med. Microbiol. 2001; 30: 49-52.
66. Isolauri E. Dietary modification of atopic disease: Use of probiotics in the prevention of atopic dermatitis. Curr Allergy Asthma Rep. 2004; 4(4): 270-5.
67. Schmidt W.P. Model of the epidemic of childhood atopy. Med Sci Monit. 2004; 10(2): HY5.
68. Kalliomaki M., Isolauri E. Role of intestinal flora in the development of allergy // Curr Opin Allergy Clin Immunol. 2003; 3(1): 15-20.
69. Rosenfeldt V., Benfeldt E., Valerius N.H., et al. Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. J Pediatr. 2004; 145(5): 612-6.
70. Majamaa H., Isolauri E. Probiotics: a novel approach in the management of food allergy. J Allergy Clin Immunol. 1997; 99(2): 179-85.
71. No author indicated. Research suggests potential role for probiotics in treating allergy. Infectious diseases in children 2003; 3: 72.
72. Kalliomaki M., Salminen S., Poussa T., et al. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet. 2003; 361 (9372): 1869-71.
73. Rautava S., Kalliomaki M., Isolauri E. Probiotics during pregnancy and breast-feeding might confer immnomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol. 2002; 109(1): 119-21.
74. Hanifin J.M., Cooper K.D., Ho V.C., et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association «Administrative Regulations for Evidence-Based Clinical Practice Guidelines». J Am Acad Dermatol. 2004; 50(3): 391-404.
75. Pelucchi C., Chatenoud L., Turati F., et al. Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: a meta-analysis. Epidemiology. 2012; 23(3): 402-14.
76. Foolad N., Brezinski E.A., Chase E.P., Armstrong A.W. Effect of nutrient supplementation on atopic dermatitis in children: a systematic review of probiotics, prebiotics, formula, and fatty acids. JAMA Dermatol. 2013; 149(3): 350-5.
77. Isolauri E., Arvola T., Sutas Y., et al. Probiotics in the management of atopic eczema. Clin Exp Allergy. 2000; 30(11): 1604-10.
78. Viljanen M., Savilahti E., Haahtela T., et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy. 2005; 60(4): 494-500.
79. Michail S.K., Stolfi A., Johnson T., Onady G.M. Efficacy of probiotics in the treatment of pediatric atopic dermatitis: a meta-analysis of randomized controlled trials. Ann Allergy Asthma Immunol. 2008; 101(5): 508-16.
80. Collet J.P., Burtin P., Gillet J., еt аl. Risk of infectious diseases in children attending different types of day-care setting. Respiration 1994; 61(suppl 1): 16-9.
81. Nafstad P., Hagen J.A., Oie L., et al. Day care centers and respiratory health. Pediatrics. 1999; 103: 753-8.
82. Hatakka K., Savilahti E., Ponka A., et al. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ. 2001; 322(7298): 1327.
83. Hojsak I., Snovak N., Abdović S., et al. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial. Clin Nutr. 2010; 29(3): 312-6.
84. Rautava S., Arvilommi H., Isolauri E. Specific probiotics in enhancing maturation of IgA responses in formula-fed infants. Pediatr Res. 2006; 60(2): 221-4.
85. Cazzola M., Pham-Thi N., Kerihuel J.C., Durand H., Bohbot S. Efficacy of a synbiotic supplementation in the prevention of common winter diseases in children: a randomized, double-blind, placebo-controlled pilot study. Ther Adv Respir Dis. 2010; 4(5): 271-8.
86. Loesche W.J. Microbiology of dental decay and periodontal disease. In: Baron’s Medical Microbiology. 4th Ed. University of Texas Medical Branch; 1996.
87. Juneja A., Kakade A. Evaluating the effect of probiotic containing milk on salivary mutans streptococci levels. J Clin Pediatr Dent. 2012; 37(1): 9-14.
88. Näse L., Hatakka K., Savilahti E., et al. Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. Caries Res. 2001; 35(6): 412-20.
89. Yamashiro Y., Nagata S. Beneficial microbes for premature infants, and children with malignancy undergoing chemotherapy. Benef Microbes. 2010; 1(4): 357-65.
90. Tillisch K., Labus J., Kilpatrick L., et al. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology. 2013; 144(7): 1394-401, 1401.e1-4.
